Boston Scientific Corporation vs Crowdstrike Holdings Inc — how do they compare? Boston Scientific Corporation trades at $51.56 (market cap $74.19B), while Crowdstrike Holdings Inc trades at $222.18 (market cap $225.95B). The key difference: Crowdstrike Holdings Inc is far larger — about 3× Boston Scientific Corporation's market cap, and Crowdstrike Holdings Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | CRWD | |
|---|---|---|
Market Cap | $74.19B | $225.95B |
Sector | Health | Technology |
52-Week High | $108.14 | $225.16 |
52-Week Low | $42.63 | $87.56 |
Enterprise Value | $86.27B | $222.22B |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
CrowdStrike (CRWD) trades at $221.01, down 1.84% today, but maintains a strong technical uptrend with bullish moving averages and support at $219. The stock has delivered consistent earnings beats, with Q1 2026 EPS of $0.28 exceeding the $0.27 estimate. Revenue growth remains robust, climbing to $3.95 billion in 2025, though net margins are slightly negative. Recent positive news includes being named a leader in IDC's MDR/MXDR report (Business Wire, August 11, 2026) and surging cybersecurity sector interest.
Outlook is cautiously optimistic given strong revenue expansion and platform adoption, but high valuation multiples (P/E 765.02, P/S 44.07) pose risks. Analyst consensus is bullish with 76% buy ratings and a $191.74 price target, though current price exceeds this. Key risks include premium valuation sensitivity, competitive pressures, and macroeconomic impacts on tech spending.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →